INTRODUCTION
Heart failure or heart failure is a complex clinical syndrome, which is characterized by the inability of the heart to pump blood throughout the body adequately, due to structural and functional disturbances of the heart (Panggabean 2014) . Heart failure is a major problem for a growing number, frequency of re-hospitalization and death. The cause of the increase is the successful handling of myocardial infarction, increasing the number of people who reach old age and they often found risk factors such as hypertension, anemia, diabetes mellitus (DM), smoking and obesity (McMurray 2012) .
Treatment of heart failure based on the pathophysiology of which is to increase CO by reducing afterload/ preload and increase cardiac contractility and prevent the remodeling of the overall target of therapy is to reduce symptoms, improve quality of life, slow disease progression, reduce morbidity and prolong life expectancy (Harvey 2009 ). The concept of pharmacological treatment of heart failure with diuretics if there is fluid retention and volume overload occurs when, Angiotensin Converting Enzyme inhibitors (ACEI) or Angiotensin Receptor Blocker (ARB) as antiremodelling and administration of ß-blockers or digitalis to increase contractility (Yancy 2013) .
Increased flow of Na+ and water causes increased excretion of potassium, the total effect of inhibition kotransporter lead chloride, sodium, potassium and H+ ions remain in the lumen thus help tereksresi that cause electrolyte disturbances such as hypokalemia, hypokalemia in use diuertik about 5-20% of patients outpatient (Dursun 2006 , Lim 2013 . The use of ACEI inhibit the formation of angiotensin I (Ang I) into angiotensin II (Ang II), as the activation of the SRAA, Ang II is a potent vasoconstrictor and stimulates the secretion of aldosterone and increased vascular resistance (afterload), Ang II also causes cell growth myocytes, hypertrophy and remodeling of the heart muscle, ACEI use inhibit the production of Ang II, thereby decreasing peripheral vascular resistance (afterload) and prevent sodium and water retention via aldosterone effects and increase bradykinin. Bradykinin stimulate the formation of nitrogen monoxide (NO) and prostaglandin that serves as antimitotic and antiremodelling (Lim 2013) , side effects of ACEI use hyperkalemia occurred around 10-38% in hospitalized patients, 10% in outpatients and more risk is increased in patients failing kidney and DM (Felker 2011) .
Treatment of heart failure recommended the use of a combination of a diuretic and ACEI, according to the guidelines of the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) in 2013 on the management of heart failure in combination with ACEI use of diuretics. The combination of both needs, diuretics reduce the burden of excess fluid (preload), pulmonary congestion and peripheral edema normally found in heart failure, while ACEI decrease afterload and heart remodeling (McMurray 2012) . The use of ACEI in the treatment of heart failure can cause hyperkalemia, whereas diuretics may occur hypokalemia, the use of combination therapies of captopril and furosemide for heart failure patients need to be monitored electrolyte patients, particularly potassium, due to hyperkalemia and hypokalemia both should be avoided in heart failure patients, can cause cardiac conduction disorders such as cardiac arrhythmia (Felker 2011) . This research will be monitoring levels of potassium in the use of a combination of captopril and furosemide therapy to patients with heart failure treated in Cardio vascular Care Unit (CVCU) Hospital Dr. Wahidin Sudirohusodo Makassar, it is necessary in order to achieve an effective treatment.
MATERIALS AND METHODS
The study was conducted using the method Prospective Observational Cross Sectional Analysis. The samples used were 37 patients. The study was conducted at room CVCU Hospital. Dr. Wahidin Sudirohusodo Makassar. Sampling was conducted from January to May 2015. The samples taken are met inclusion criteria and get rid of the exclusion. After signing the informed consent will be monitoring during therapy and blood sampling performed on samples of research and examination potassium level is performed in the Laboratory of Hospital Dr. Wahidin Sudirohusodo Makassar.
RESULTS
In Table 1 shows the demographic data of patients who serve as research samples, including, gender, age, diagnosis, potassium levels after therapy and the type of combination therapy given. The dose in this study there is no intervention either on captopril and furosemide therapy, dose adjusted to the patient's condition. Captopril tablets given orally at a dose strengths of 6.25 mg, 12.5 mg and 25 mg 3 times daily administration. Captopril given small doses ranging from 6.25 mg can be titrated up to a maximum dose, given three times a day.
Furosemide given in this study through iv in dosage form of 10 mg/ml in ampoules 2 ml, administration of furosemide iv starting dose of 40 mg a day may be increased, doses every 8 hours or 12 hours, through the provision of syringe pump or bolus and intermittent until a stable condition and continued with oral furosemide 40 mg 1x. Patients who received the combination therapy of 6.25 mg captopril and furosemide 40 mg as 6 patients (16.2%), captopril 12.5 mg and 40 mg of furosemide were 9 patients (24.3%), captopril and furosemide 12.5 mg 80 mg of 16 patients (43.3%), captopril 25 mg and furosemide 40 mg as many as three patients (8.1%) and captopril 25 mg and furosemide 80 mg as many as three patients (8.1%). A total of 37 patients in this study before getting combination therapy normal potassium levels (3,5-5.0 mmol/L) (K0). Observations potassium levels before and after administration of furosemide and captopril combination therapy can be seen in Table 4 that have been processed statistically 
DISCUSSION
This study was conducted to monitor potassium levels in heart failure patients after administration of the combination therapy of captopril and furosemide, the parameters used in patients that levels of electrolytes, especially potassium levels in patients, serum urea and creatinine. In the study sample as many as 37 patients, there was no intervention on the dose and route of administration depending on the patient's condition while being treated by the clinician. Patients in this study were patients with heart failure NYHA II-III were treated at CVCU day care during started 4 days.
Administration of drugs in the room CVCU usually in the form of iv with intermittent or bolus administration to get the effect more quickly, and be able to use a syringe pump to get a fixed dose and continuous and can be stopped if it is not needed. Giving oral form is given if the condition is stable and there is only preparation in tablet form.
Handling of patients with heart failure by reducing afterload, through the use of ACEI by inhibiting the formation of Ang II from Ang I, Ang II is a powerful vasokontriktor, stimulates the secretion of aldosterone and other vasopressin (Lim 2013) . Inhibition of Ang II is the foundation of therapy for heart failure, according to the ACCF/AHA 2013 Award ACEI is recommended for all patients with heart failure to reduce mortality and morbidity (grade Ia), unless there are contra-indications, ACEI inhibit the formation of Ang II and degradation Bradikinin and stimulates synthesis vasodilating substances including PEG and NO. ACEI effectively prevent left ventricular hypertrophy by reducing direct stimulation of Ang II also cause remodeling (Hunt, 2004 , Yancy 2013 .
ACEI usually started on a low dose, as anti remodeling of the heart and can then be titrated up within a few weeks up to a maximum dose that can be tolerated. However, if there are limitations in increasing doses because of side effects, the low doses can still provide considerable advantages for both mortality and improvement of symptoms of heart failure (Yancy 2013) , the side effects that can be caused to the use of ACEI occurrence of hyperkalemia in hospitalized patients 10-38%, the 10% of outpatients and coughing 3-15% (Felker 2011) .
Captopril is an ACEI group sulfhydril not prodrug, a short-acting has a direct effect on the heart in terms of preventing remodeling and expansion inhibit myocardial damage, treatment is initiated from the 3 times daily dose of 6.25 mg per day may be increased (Kabo 2010) . The mechanism of hyperkalemia in the use of ACEI, where ACEI inhibit the formation of Ang II, so that prisoners peripheral vascular decreased (afterload) and prevent sodium and water retention through the effects of aldosterone by the mechanism of sodium reabsorbed in the distal tubule and duct kolektus in exchange for K+ with H+ through the canal sodium aldosteronesensitive potassium secreted later, the inhibition of ang II by ACEI will also inhibit potassium secretion of aldosterone thus also decreases will lead to hyperkalemia (McMurray 2012).
According to the CCS heart failure management guidelines (Canadian Cardiovascular Society 2012) recommends iv diuretics as first-line therapy in patients with heart failure, CCS recommends the use of furosemide in patients requiring iv diuretics, either intermittent doses (2-3 times daily) or intravenous continuously. Furosemide is a sulfonamide-derived class, the initial dose of furosemide administration is 20-40 mg daily doses of 40-240 mg for treatment of heart failure (McMurray 2012).
In this study, patients received furosemide in intermittent 2 x 20 mg and 2 x 40 mg iv was a continuous infusion using a syringe pump rate of 10 mg/hour for 8 hours, in case of hypokalemia on the use of furosemide, it can be stopped, or in combination with a potassium-sparing diuretic such as spironolactone and if hypotension use of furosemide may be suspended or terminated. Use of furosemide can cause hypokalemia, the mechanism of action of furosemide is co-transporter inhibit Na+/ K+/2Cl-that play a role in the transport of chloride through a layer of cells on Thick Assending Limb (TAL) loop of Henle.
Hypokalemia and hyperkalemia in patients with heart failure should be avoided, because they can cause disturbances in cardiac conduction, causing ventricular arrhythmias that can cause sudden death (Dursun 2006) . Therefore potassium levels in heart failure patients should be maintained at normal levels of potassium and potassium levels should be monitored as well as the patient's ECG.
CONCLUSION
Monitoring of potassium levels in heart failure patients should remains to be done to avoid hyper or hypokalium conditions. In this study there was no significant difference to the patient's potassium levels, and most patients have normal potassium levels.
